FDA approves GSK’s anemia drug with safety warning — after batting back similar drugs — Endpoints News

Last year it offered a disappointing stretch for biotech, with fewer deals than expected and lots more headwinds. Endpoints News Editor-in-Chief John Carroll sat down with some of the industry’s top dealmakers to explore what happened, and what’s ahead in 2023. This transcript has been edited for brevity and clarity.

John Carroll:

I’d say this is one of the most important conversations that’s going on right now. Particularly, of course, at JP Morgan, because so many people have come here, specifically to get involved in a deal, to see what they can do about a deal, to see what the potential deal is, where things are headed, what the trends are. Everything that we’re going to be covering here in the next hour.

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Leave a Comment

Your email address will not be published. Required fields are marked *